<DOC>
	<DOCNO>NCT02701205</DOCNO>
	<brief_summary>This randomize , double-blind , multicentral clinical trial investigate efficacy safety Recombinant Human TNF Receptor-Ig Fusion Protein Injection ( Qiangke® ) treatment Moderate Severe Plaque Psoriasis . The primary purpose assess different maintain treatment programme Moderate Severe plaque psoriasis Qiangke® . And second purpose ass efficacy safety Qiangke® Moderate Severe Plaque Psoriasis . The trial include 216 Moderate Severe plaque psoriasis patient , first stage randomize divide three group : full-dose Qiangke® group , half-dose Qiangke® group placebo group.And blind stage last 12 week . Then second stage , patient receive 50mg qw Qiangke® additional 12 week .</brief_summary>
	<brief_title>Safety Efficacy Study Etanercept ( Qiangke® ) Treat Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>Psoriasis chronic inflammatory skin disease lead significant physical psychologic distress patients.Recombinant Human TNF Receptor-Ig Fusion Protein Injection ( Qiangke® ) block role cytokine tumor necrosis factor ( TNF ) -alpha . TNF-α play major role pathophysiology Psoriasis（PsO）and Psoriatic Arthritis ( PsA ) . TNF-α level elevate psoriatic skin lesion , serum sample , synovial fluid . Anti-TNF-α therapy show efficacy treat psoriatic skin lesion , joint pain swelling , enthesitis , dactylitis plus ability improve mobility , reduce radiographic progression disease , influence quality life parameter . Qiangke® dimeric , soluble fusion protein consist extracellular ligand bind portion TNF receptor link Fc portion human Immunoglobulin gamma-1（IgG1） . It capable bind neutralize soluble TNF transmembrane TNF . It alter neutrophil migration dendritic cell T-cell maturation migration , thus decrease local systemic production pro-inflammatory cytokine subsequent effect .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Male Female , age 1865 , Asian . 2 . Freely provide verbal write informed consent . 3 . Consent use effective contraception trial period . 4 . Participant clinical diagnosis psoriasis least 6 month , moderate severe plaque psoriasis 5 . Participant must Psoriasis Area Severity Index score great equal 12 baseline visit Body Surface Area involvement great equal 10 % baseline visit . 6 . Participant previous exposure systemic psoriasis therapy phototherapy , ideal . 7 . Meet follow criterion Tuberculosis screening : A. prior history occult active tuberculosis . B . No sign symptom active tuberculosis history / physical examination . C. first 6 week trial , tuberculosis screen test meet requirement trial . 8 . Laboratory screen result : Hemoglobin≥110g/L.White blood cell≥4 * 109 /L . Neutrophil≥1.5 * 109/L.Platelet≥100 * 109/L.Serum alanine aminotransferase / aspartate aminotransferase 1.5 time upper limit normal.Serum creatinine exceed 1.5 mg/dL ( International unit : ≤133 mol/L ) . 9 . During first 2 week study , Participant must stop adjuvant therapy include traditional Chinese medicine acupuncture . 10 . Hepatitis B ( HBV ) screen compliance requirement test . 11 . Weight≥60Kg . 1 . Pustular , erythrodermic , and/or guttate form psoriasis . 2 . Participant treat TNF antagonist within 6 week prior Baseline visit . 3 . Participant treat Other biological agent within 6 week prior Baseline visit . 4 . Participant treat Phototherapy systemic antipsoriatic treatment ( : Methotrexate（MTX）， acitretin , cyclosporine , Total Glucosides Paeony（TGP） , treatment psoriasis relate Chinese medicine , etc . ) systemic corticosteroid treatment within 4 week prior Baseline visit . 5 . Participant treat Topical corticosteroid therapy , vitamin A D analogue Anthralin within 2 week prior Baseline visit . 6 . Participant receive drug drug 's metabolism le 7 half life Baseline visit . 7 . Participant plan pregnant breast feed father study . 8 . The history occult active granuloma infection , include histoplasmosis , coccidioidomycosis . 9 . Participant suffer Non Mycobacterium tuberculosis infection opportunistic infection ( cytomegalovirus sense dyeing , Pneumocystis carinii pneumonia , aspergillosis ) within 6 week prior Baseline visit . 10 . The close contact history active tuberculosis patient Tuberculosis screen result meet requirement . 11 . Participant suffer severe infection ( example hepatitis , pneumonia , acute pyelonephritis sepsis ) , participant use intravenous antibiotic infection within 6 week prior Baseline visit . 12 . Participant suffer chronic recurrent infection present , include ( limited ) chronic kidney infection disease chronic chest infectious disease ( bronchial dilation ) , sinusitis , recurrent urinary tract infection ( recurrent pyelonephritis chronic non remission cystitis ) , open , overflow liquid infection skin wound ulcer . 13 . Human immunodeficiency virus ( HIV ) antibody positive . 14 . Hepatitis B virus ( HBV ) screen result meet requirement . 15 . Hepatitis C virus ( HCV ) antibody positive . 16 . Participant demyelinate disease multiple sclerosis optic neuritis . 17 . A history congestive heart failure , include asymptomatic congestive heart failure . 18 . A history sign lymph node hyperplasia , include lymphoma suggestive possible sign size location enlarge lymph node history clinically significant enlargement spleen . 19 . Participant symptom sign severe , progressive uncontrolled kidney , liver , blood , gastrointestinal , endocrine , lung , heart , nerve , mental brain disease . 20 . There history malignancy previous history . 21 . Joint prosthesis yet remove replace .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Skin Disease</keyword>
</DOC>